Diabetes-Induced Birth Defects: What Do We Know? What Can We Do?

被引:52
|
作者
Reece, E. Albert [1 ]
机构
[1] Univ Maryland, Sch Med, Baltimore, MD 21210 USA
关键词
Antioxidant therapy; Birth defects; Fatty acid; Folic acid; Diabetic embryopathy; Dietary supplementation; Hyperglycemia; Infant mortality; Pregnancy; Glucose control; Molecular pathogenesis; Preconception care; Diabetes; INOSITOL POLYPHOSPHATES; CONGENITAL-ANOMALIES; SUPEROXIDE-DISMUTASE; INSULIN THERAPY; UNITED-STATES; EMBRYOPATHY; PREGNANCY; HYPERGLYCEMIA; PREVENTION; ACTIVATION;
D O I
10.1007/s11892-011-0251-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Birth defects are the leading cause of infant mortality in the United States, which has one of the highest infant mortality rates in the developed world. Many of these birth defects can be attributed to pre-existing, or pregestational, diabetes in pregnancy, which significantly increases a mother's risk of having a child with a major birth defect. Strict preconceptional and early pregnancy glucose control, supplementation with multivitamins and fatty acids, and lower glycemic dietary management have been shown to reduce the incidence of birth defects in experimental and epidemiologic studies. However, because more than half of pregnancies are unplanned, these methods are not generalizable across the population. Thus, better interventions are urgently needed. Based on what we know about the molecular pathophysiology of diabetic embryopathy, our laboratory and others are developing interventions against to key molecular targets in this multifactorial disease process.
引用
收藏
页码:24 / 32
页数:9
相关论文
共 50 条
  • [21] Ebola: What do we need to know?
    Dinh, A.
    Severin, A.
    Havette, P.
    Peyrethon, C.
    Descatha, A.
    ARCHIVES DES MALADIES PROFESSIONNELLES ET DE L ENVIRONNEMENT, 2015, 76 (01) : 40 - 42
  • [22] Brain temperature: What do we know?
    Rango, Mario
    Arighi, Andrea
    Bresolin, Nereo
    NEUROREPORT, 2012, 23 (08) : 483 - 487
  • [23] Pregnancy and antibody-mediated CNS disorders: What do we know and what should we know?
    Cortese, Rosa
    Mariotto, Sara
    Mancinelli, Chiara Rosa
    Tortorella, Carla
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [24] Zika virus: what do we know?
    Musso, D.
    Baud, D.
    Gubler, D. J.
    CLINICAL MICROBIOLOGY AND INFECTION, 2016, 22 (06) : 494 - 496
  • [25] Lipids and vascular disease: what we do and do not know
    Sniderman, AD
    Cianflone, K
    CLINICA CHIMICA ACTA, 1999, 286 (1-2) : 7 - 22
  • [26] Gestational Diabetes and Preterm Birth: What Do We Know? Our Experience and Mini-Review of the Literature
    Preda, Agnesa
    Iliescu, Dominic-Gabriel
    Comanescu, Alexandru
    Zorila, George-Lucian
    Vladu, Ionela Mihaela
    Fortofoiu, Mircea-Catalin
    Tenea-Cojan, Tiberiu Stefanita
    Preda, Silviu-Daniel
    Diaconu, Ileana-Diana
    Mota, Eugen
    Gheorghe, Ioan-Ovidiu
    Mota, Maria
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (14)
  • [27] Mitochondrial Dysfunction in Aristolochic Acid I-Induced Kidney Diseases: What We Know and What We Do Not Know
    Lukinich-Gruia, Alexandra T.
    Calma, Crenguta L.
    Szekely, Flavia A. E.
    Cristea, Iustina-Mirabela
    Pricop, Maria-Alexandra
    Simina, Alina-Georgiana
    Ordodi, Valentin L.
    Pavlovic, Nikola M.
    Tatu, Calin A.
    Paunescu, Virgil
    APPLIED SCIENCES-BASEL, 2024, 14 (17):
  • [28] Multiple Gestations and Hypertensive Disorders of Pregnancy: What Do We Know?
    Narang, Kavita
    Szymanski, Linda M.
    CURRENT HYPERTENSION REPORTS, 2021, 23 (01)
  • [29] Infertility and Preterm Delivery: What Do We Know and Where Do We Go from Here?
    Wise, Lauren A.
    PAEDIATRIC AND PERINATAL EPIDEMIOLOGY, 2015, 29 (02) : 97 - 100
  • [30] Adolescent gun violence prevention: what we know, and what we can do to keep young people safe
    Dodson, Nancy A.
    CURRENT OPINION IN PEDIATRICS, 2016, 28 (04) : 441 - 446